202 related articles for article (PubMed ID: 25997541)
1. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Earl J; Rico D; Carrillo-de-Santa-Pau E; Rodríguez-Santiago B; Méndez-Pertuz M; Auer H; Gómez G; Grossman HB; Pisano DG; Schulz WA; Pérez-Jurado LA; Carrato A; Theodorescu D; Chanock S; Valencia A; Real FX
BMC Genomics; 2015 May; 16(1):403. PubMed ID: 25997541
[TBL] [Abstract][Full Text] [Related]
2. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
Kompier LC; Lurkin I; van der Aa MN; van Rhijn BW; van der Kwast TH; Zwarthoff EC
PLoS One; 2010 Nov; 5(11):e13821. PubMed ID: 21072204
[TBL] [Abstract][Full Text] [Related]
3. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
[TBL] [Abstract][Full Text] [Related]
4. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
Bou Zerdan M; Bratslavsky G; Jacob J; Ross J; Huang R; Basnet A
Mol Diagn Ther; 2023 Jul; 27(4):475-485. PubMed ID: 37195586
[TBL] [Abstract][Full Text] [Related]
5. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
Choi W; Ochoa A; McConkey DJ; Aine M; Höglund M; Kim WY; Real FX; Kiltie AE; Milsom I; Dyrskjøt L; Lerner SP
Eur Urol; 2017 Sep; 72(3):354-365. PubMed ID: 28365159
[TBL] [Abstract][Full Text] [Related]
6. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
Groeneveld CS; Sanchez-Quiles V; Dufour F; Shi M; Dingli F; Nicolle R; Chapeaublanc E; Poullet P; Jeffery D; Krucker C; Maillé P; Vacherot F; Vordos D; Benhamou S; Lebret T; Micheau O; Zinovyev A; Loew D; Allory Y; de Reyniès A; Bernard-Pierrot I; Radvanyi F
Eur Urol; 2024 May; 85(5):483-494. PubMed ID: 37380559
[TBL] [Abstract][Full Text] [Related]
7. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
Posada JM; Yakirevich E; Kamat AM; Sood A; Jacob JM; Bratslavsky G; Grivas P; Spiess PE; Li R; Necchi A; Mega AE; Golijanin DJ; Pavlick D; Huang RSP; Lin D; Danziger N; Sokol ES; Sivakumar S; Ross JS; Cheng L
Mod Pathol; 2024 Mar; 37(3):100424. PubMed ID: 38219954
[TBL] [Abstract][Full Text] [Related]
8. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
Leary JB; Enright T; Bakaloudi DR; Basnet A; Bratslavsky G; Jacob J; Spiess PE; Li R; Necchi A; Kamat AM; Pavlick DC; Danziger N; Huang RSP; Lin DI; Cheng L; Ross J; Talukder R; Grivas P
Target Oncol; 2024 May; 19(3):447-458. PubMed ID: 38570422
[TBL] [Abstract][Full Text] [Related]
9. Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA.
Togneri FS; Ward DG; Foster JM; Devall AJ; Wojtowicz P; Alyas S; Vasques FR; Oumie A; James ND; Cheng KK; Zeegers MP; Deshmukh N; O'Sullivan B; Taniere P; Spink KG; McMullan DJ; Griffiths M; Bryan RT
Eur J Hum Genet; 2016 Aug; 24(8):1167-74. PubMed ID: 26757983
[TBL] [Abstract][Full Text] [Related]
10. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer.
Kiemeney LA; Sulem P; Besenbacher S; Vermeulen SH; Sigurdsson A; Thorleifsson G; Gudbjartsson DF; Stacey SN; Gudmundsson J; Zanon C; Kostic J; Masson G; Bjarnason H; Palsson ST; Skarphedinsson OB; Gudjonsson SA; Witjes JA; Grotenhuis AJ; Verhaegh GW; Bishop DT; Sak SC; Choudhury A; Elliott F; Barrett JH; Hurst CD; de Verdier PJ; Ryk C; Rudnai P; Gurzau E; Koppova K; Vineis P; Polidoro S; Guarrera S; Sacerdote C; Campagna M; Placidi D; Arici C; Zeegers MP; Kellen E; Gutierrez BS; Sanz-Velez JI; Sanchez-Zalabardo M; Valdivia G; Garcia-Prats MD; Hengstler JG; Blaszkewicz M; Dietrich H; Ophoff RA; van den Berg LH; Alexiusdottir K; Kristjansson K; Geirsson G; Nikulasson S; Petursdottir V; Kong A; Thorgeirsson T; Mungan NA; Lindblom A; van Es MA; Porru S; Buntinx F; Golka K; Mayordomo JI; Kumar R; Matullo G; Steineck G; Kiltie AE; Aben KK; Jonsson E; Thorsteinsdottir U; Knowles MA; Rafnar T; Stefansson K
Nat Genet; 2010 May; 42(5):415-9. PubMed ID: 20348956
[TBL] [Abstract][Full Text] [Related]
11. Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms?
Dudek AM; Grotenhuis AJ; Vermeulen SH; Kiemeney LA; Verhaegh GW
Int J Mol Sci; 2013 Jun; 14(6):12346-66. PubMed ID: 23752272
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.
Zuiverloon TCM; de Jong FC; Costello JC; Theodorescu D
Bladder Cancer; 2018 Apr; 4(2):169-183. PubMed ID: 29732388
[TBL] [Abstract][Full Text] [Related]
13. Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies.
Earl J; Rico D; Carrillo-de-Santa-Pau E; Rodríguez-Santiago B; Méndez-Pertuz M; Auer H; Gómez G; Grossman HB; Pisano DG; Schulz WA; Pérez-Jurado LA; Carrato A; Theodorescu D; Chanock S; Valencia A; Real FX
BMC Genomics; 2015 Nov; 16(1):1019. PubMed ID: 26621286
[No Abstract] [Full Text] [Related]
14. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.
Eriksson P; Aine M; Veerla S; Liedberg F; Sjödahl G; Höglund M
BMC Med Genomics; 2015 May; 8():25. PubMed ID: 26008846
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for bladder cancer.
Fuge O; Vasdev N; Allchorne P; Green JS
Res Rep Urol; 2015; 7():65-79. PubMed ID: 26000263
[TBL] [Abstract][Full Text] [Related]
16. Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Earl J; Rico D; Carrillo-de-Santa-Pau E; Rodríguez-Santiago B; Méndez-Pertuz M; Auer H; Gómez G; Grossman HB; Pisano DG; Schulz WA; Pérez-Jurado LA; Carrato A; Theodorescu D; Chanock S; Valencia A; Real FX
BMC Genomics; 2016 Oct; 17(1):829. PubMed ID: 27782819
[No Abstract] [Full Text] [Related]
17. Spatial genomic heterogeneity within localized, multifocal prostate cancer.
Boutros PC; Fraser M; Harding NJ; de Borja R; Trudel D; Lalonde E; Meng A; Hennings-Yeomans PH; McPherson A; Sabelnykova VY; Zia A; Fox NS; Livingstone J; Shiah YJ; Wang J; Beck TA; Have CL; Chong T; Sam M; Johns J; Timms L; Buchner N; Wong A; Watson JD; Simmons TT; P'ng C; Zafarana G; Nguyen F; Luo X; Chu KC; Prokopec SD; Sykes J; Dal Pra A; Berlin A; Brown A; Chan-Seng-Yue MA; Yousif F; Denroche RE; Chong LC; Chen GM; Jung E; Fung C; Starmans MH; Chen H; Govind SK; Hawley J; D'Costa A; Pintilie M; Waggott D; Hach F; Lambin P; Muthuswamy LB; Cooper C; Eeles R; Neal D; Tetu B; Sahinalp C; Stein LD; Fleshner N; Shah SP; Collins CC; Hudson TJ; McPherson JD; van der Kwast T; Bristow RG
Nat Genet; 2015 Jul; 47(7):736-45. PubMed ID: 26005866
[TBL] [Abstract][Full Text] [Related]
18. High CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder.
Wang B; Liu H; Dong X; Wu S; Zeng H; Liu Z; Wan D; Dong W; He W; Chen X; Zheng L; Huang J; Lin T
Oncotarget; 2015 Aug; 6(24):20204-14. PubMed ID: 26001293
[TBL] [Abstract][Full Text] [Related]
19. The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.
Lin X; Stenvang J; Rasmussen MH; Zhu S; Jensen NF; Tarpgaard LS; Yang G; Belling K; Andersen CL; Li J; Bolund L; Brünner N
BMC Genomics; 2015 May; 16(1):404. PubMed ID: 25997618
[TBL] [Abstract][Full Text] [Related]
20. Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer.
Du M; Shi D; Yuan L; Li P; Chu H; Qin C; Yin C; Zhang Z; Wang M
Sci Rep; 2015 May; 5():10437. PubMed ID: 26014226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
